Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- J.P.S Henriques
- Target Recruit Count
- 50
- Registration Number
- NCT06103266
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Lebanese University
- Target Recruit Count
- 500
- Registration Number
- NCT06065592
- Locations
- 🇱🇧
Haykel Hospital, Tripoli, North Lebanon, Lebanon
🇱🇧Lebanese University, Tripoli, North Lebanon, Lebanon
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3691397
- Registration Number
- NCT05838664
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Anticoagulation in Post MI LV Thrombus Trial in Nepal
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shahid Gangalal National Heart Centre
- Target Recruit Count
- 196
- Registration Number
- NCT05794399
- Locations
- 🇳🇵
Nepal Health Research Council, Kathmandu, Bagmati, Nepal
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Target Recruit Count
- 140
- Registration Number
- NCT05750758
- Locations
- 🇨🇳
Fuwai central China cardiovascular Hospital, Zhengzhou, Henan, China
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 6660
- Registration Number
- NCT05735639
- Locations
- 🇬🇧
Imperial College Hospital NHS Foundation Trust, London, United Kingdom
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-12-21
- Target Recruit Count
- 1180
- Registration Number
- NCT05700266
Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion
- Conditions
- Interventions
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-01-04
- Target Recruit Count
- 150
- Registration Number
- NCT05671276
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 10
- Registration Number
- NCT05410275
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 700
- Registration Number
- NCT05399277
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.